Compare TG Therapeutics Inc (TGTX) vs Wayfair Inc (W) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
TG Therapeutics Inc vs Wayfair Inc — how do they compare? TG Therapeutics Inc trades at $49.44 (market cap $7.64B), while Wayfair Inc trades at $102.74 (market cap $14.14B). The key difference: Wayfair Inc is the larger of the two by market cap. Which is the better fit depends on your goals.
| TGTX | W | |
|---|---|---|
Market Cap | $7.64B | $14.14B |
Sector | Health | Consumer Cyclical |
52-Week High | $59.06 | $119.05 |
52-Week Low | $26.94 | $57.40 |
Enterprise Value | $7.84B | $16.47B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
TG Therapeutics (TGTX) trades at $49.50, up 0.69% today, with a bearish technical signal from moving averages despite neutral oscillators. The company reported strong revenue growth, with Q2 2026 sales reaching $240 million and raised full-year guidance to $950 million, though it missed earnings estimates for three consecutive quarters. Profitability metrics remain robust with a net income margin of 55.22% and ROE exceeding 100%, but valuation ratios like EV/EBITDA at 56.26 suggest premium pricing.
The outlook is mixed: bullish analyst sentiment with an 84.6% buy rating and a $63.75 price target offers upside potential, driven by Briumvi's commercial success and expansion into schizophrenia trials. However, risks include earnings misses, a shareholder investigation into fiduciary duties, and high cash burn in 2025. Investors should weigh strong revenue momentum against execution risks and elevated valuations.
Wayfair (W) trades at $102.79, down 0.52% on the day, with a bullish technical signal supported by a golden cross and recent 30% post-earnings rally. Q2 2026 EPS of $0.95 beat estimates, driven by 7.5% revenue growth and strong U.S. demand, though net margins remain negative. Analyst consensus is bullish with a $122 price target, citing market share gains and margin expansion prospects.
Outlook: Growth momentum and positive sentiment offer upside potential, but risks include persistent losses, high debt-to-asset ratio (95.11% in 2025), and volatile consumer spending. Investors should weigh robust U.S. performance against international weakness and profitability challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →About Wayfair Inc
Wayfair is a global leader in home goods, operating a massive digital marketplace that connects millions of consumers with thousands of suppliers. It utilizes an asset-light, inventory-light model combined with a proprietary logistics network (CastleGate) and an accelerating brick-and-mortar presence to deliver an end-to-end shopping experience for everything from decor to full home renovations.
Read more on W →
